Close
Close
Treatment News

TxCell: Presentation of New Transplantation CAR-Treg Data at ESOT 2017

2.77777777778
2.8 from 9 votes
Thursday, September 14, 2017

Valbonne, France – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, announces that new preclinical data will be presented at the 18th Congress of the European Society for Organ Transplantation (ESOT) to be held in Barcelona from Sept 24-27, 2017.

An oral presentation entitled 'Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor' will be made on September 26, 2017 at 11.50 am CEST by Megan Levings, PhD, Professor, Department of Surgery, University of British Columbia (UBC) and Head, Childhood Diseases Research Theme, BC Children's Hospital in Vancouver, Canada. TxCell and UBC have been collaborating on the development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation since October 2016.

Further details will be communicated in due time. The full program is available on the conference website http://esot2017.esot.org/.

About TxCell – www.txcell.com
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohn's disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplant rejection.
TxCell is the only clinical-stage cellular therapy company fully dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing antigen-specific Tregs. This antigen specificity may either come from genetic modifications with Chimeric Antigen Receptor (CAR) or from pre-existing Treg cell T-Cell Receptor (TCR). TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs.

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

Next events
Scientific and medical conferences
Sept 20-21 Phacilitate Leaders Forum Europe Berlin (DE)
Sept 24-27 ESOT 2017 (European Society for Organ Transplantation) Barcelona (SP)
Sept 26 Journée « Bioproduction des immunothérapies en France » Paris (FR)
Oct 9-11 Final conference on the COST 'A FACTT' project Barcelona (SP)
Oct 17-20 ESGCT 2017 (European Society of Gene & Cell Therapy) Berlin (DE)
Financial and business conferences
Sept 26-27 Annual Biotech in Europe Investor Forum (Sachs Associates) Basel (CH)
Oct 4-5 Large & Midcap Event Paris Paris (FR)
Oct 4-5 Cell & Gene Meeting on the Mesa La Jolla (US)
Nov 6-9 BIO-Europe Berlin (DE)
Nov 9 5th Annual European Advanced Therapies Investor Day London (UK)
Nov 14 Inv€$tival Showcase London (UK)
Nov 15-16 Jefferies 2017 Global Healthcare Conference London (UK)
Nov 23-24 Actionaria Paris (FR)

Contact

Neil Hunter
Life Science & Corporate Communications Director
Image Box Ltd.
T: +44 (0) 20 8943 4685
D: +44 (0) 20 3747 3302
M: +44 (0) 777 333 6517
E: neil.hunter@imageboxpr.co.uk
W: www.imageboxpr.co.uk
Twitter: @Imageboxlspr


Valbonne, France, September 13, 2017 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces that new preclinical data will be presented at the 18th Congress of the European Society for Organ Transplantation (ESOT) to be held in Barcelona from Sept 24-27, 2017.

An oral presentation entitled ‘Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor’ will be made on September 26, 2017 at 11.50 am CEST

 by Megan Levings, PhD, Professor, Department of Surgery, University of British Columbia (UBC) and Head, Childhood Diseases Research Theme, BC Children's Hospital in Vancouver, Canada. TxCell and UBC have been collaborating on the development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation since October 2016.

 

Further details will be communicated in due time. The full program is available on the conference website http://esot2017.esot.org/

About TxCell – www.txcell.com   
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplant rejection. 

TxCell is the only clinical-stage cellular therapy company fully dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing antigen-specific Tregs. This antigen specificity may either come from genetic modifications with Chimeric Antigen Receptor (CAR) or from pre-existing Treg cell T-Cell Receptor (TCR). TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs. 

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

Next events   
Scientific and medical conferences
Sept 20-21 Phacilitate Leaders Forum Europe   Berlin (DE)
Sept 24-27 ESOT 2017 (European Society for Organ Transplantation) Barcelona (SP)
Sept 26 Journée « Bioproduction des immunothérapies en France » Paris (FR)
Oct 9-11 Final conference on the COST ‘A FACTT’ project Barcelona (SP)
Oct 17-20 ESGCT 2017 (European Society of Gene & Cell Therapy) Berlin (DE)

Financial and business conferences

Sept 26-27 Annual Biotech in Europe Investor Forum (Sachs Associates) Basel (CH)
Oct 4-5 Large & Midcap Event Paris Paris (FR)
Oct 4-5 Cell & Gene Meeting on the Mesa La Jolla (US)
Nov 6-9 BIO-Europe Berlin (DE)
Nov 9 5th Annual European Advanced Therapies Investor Day London (UK)
Nov 14 Inv€$tival Showcase London (UK)
Nov 15-16 Jefferies 2017 Global Healthcare Conference  London (UK)
Nov 23-24 Actionaria Paris (FR)
Source: TxCell SA
2.77777777778
2.8 from 9 votes
Free Newsletter
Related Videos